• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension.西地那非作为儿童原发性肺动脉高压的一种选择性肺血管扩张剂。
Heart. 2000 Aug;84(2):E4. doi: 10.1136/heart.84.2.e4.
2
Sildenafil treatment of primary pulmonary hypertension.西地那非治疗原发性肺动脉高压
Can Respir J. 2003 Jan-Feb;10(1):48-50. doi: 10.1155/2003/612905.
3
Sildenafil as a treatment for pulmonary hypertension.西地那非作为肺动脉高压的一种治疗方法。
Arch Dis Child. 2003 Sep;88(9):827-8. doi: 10.1136/adc.88.9.827.
4
Marked improvement with sildenafil in a patient with primary pulmonary hypertension unresponsive to epoprostenol.一名对依前列醇无反应的原发性肺动脉高压患者使用西地那非后有显著改善。
Intern Med. 2004 Oct;43(10):945-50. doi: 10.2169/internalmedicine.43.945.
5
Sildenafil as adjunct therapy to high-dose epoprostenol in a patient with pulmonary veno-occlusive disease.西地那非作为高剂量依前列醇的辅助治疗用于一名肺静脉闭塞病患者。
Heart Lung Circ. 2006 Apr;15(2):139-42. doi: 10.1016/j.hlc.2005.07.002. Epub 2005 Oct 17.
6
Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.在其许可适应症范围内,依前列醇、伊洛前列素、波生坦、西他生坦和西地那非治疗肺动脉高压的临床和成本效益:系统评价和经济评估。
Health Technol Assess. 2009 Oct;13(49):1-320. doi: 10.3310/hta13490.
7
Sildenafil in the management of primary pulmonary hypertension.
Indian Heart J. 2002 May-Jun;54(3):297-300.
8
[The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma].[特发性肺动脉高压的治疗及其与系统性硬化症的关系]
Rev Med Interne. 2007 Dec;28 Suppl 4:S273-6. doi: 10.1016/j.revmed.2007.09.012. Epub 2007 Oct 8.
9
[The combined use of sildenafil with epoprostenol in a patient with primary pulmonary hypertension].[西地那非与依前列醇联合用于一名原发性肺动脉高压患者的治疗]
Anadolu Kardiyol Derg. 2002 Sep;2(3):262-4.
10
Treatment of rebound pulmonary hypertension: why not sildenafil?rebound肺动脉高压的治疗:为何不选用西地那非? (注:这里的“rebound pulmonary hypertension”最好结合上下文准确翻译,比如“复发性肺动脉高压”等更合适的表述,但按要求未做调整)
Anesthesiology. 2004 Dec;101(6):1480; author reply 1481. doi: 10.1097/00000542-200412000-00039.

引用本文的文献

1
The Emergence of Oral Sildenafil for Pulmonary Hypertension Management.口服西地那非用于肺动脉高压治疗的出现。
Pulm Circ. 2025 Aug 4;15(3):e70150. doi: 10.1002/pul2.70150. eCollection 2025 Jul.
2
Modulating NO-GC Pathway in Pulmonary Arterial Hypertension.调节肺动脉高压中的 NO-GC 通路。
Int J Mol Sci. 2023 Dec 19;25(1):36. doi: 10.3390/ijms25010036.
3
Vasodilator therapy for pulmonary hypertension in children: a national study of patient characteristics and current treatment strategies.儿童肺动脉高压的血管扩张剂治疗:一项关于患者特征和当前治疗策略的全国性研究。
Pulm Circ. 2021 Dec 13;11(4):20458940211057891. doi: 10.1177/20458940211057891. eCollection 2021 Oct-Dec.
4
Pharmacological preconditioning with phosphodiestrase inhibitor: an answer to stem cell survival against ischemic injury through JAK/STAT signaling.磷酸二酯酶抑制剂的药物预处理:通过 JAK/STAT 信号通路提高干细胞对缺血损伤的存活能力。
Heart Fail Rev. 2020 Mar;25(2):355-366. doi: 10.1007/s10741-019-09822-0.
5
Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management.儿科肺动脉高压:定义、分类、诊断和治疗的更新。
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01916-2018. Print 2019 Jan.
6
Sildenafil Use in Children with Pulmonary Hypertension.西地那非在儿童肺动脉高压中的应用。
J Pediatr. 2019 Feb;205:29-34.e1. doi: 10.1016/j.jpeds.2018.09.067. Epub 2018 Nov 2.
7
Sildenafil for pulmonary hypertension in neonates.西地那非用于新生儿肺动脉高压
Cochrane Database Syst Rev. 2017 Aug 4;8(8):CD005494. doi: 10.1002/14651858.CD005494.pub4.
8
Bone Morphogenetic Protein-Based Therapeutic Approaches.基于骨形态发生蛋白的治疗方法。
Cold Spring Harb Perspect Biol. 2018 Apr 2;10(4):a022327. doi: 10.1101/cshperspect.a022327.
9
Ocular toxicity assessment of chronic sildenafil therapy for pulmonary arterial hypertension.慢性西地那非治疗肺动脉高压的眼部毒性评估
Graefes Arch Clin Exp Ophthalmol. 2016 Jun;254(6):1167-74. doi: 10.1007/s00417-016-3352-8. Epub 2016 Apr 19.
10
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.磷酸二酯酶抑制剂在肺血管疾病管理中的作用。
Glob Cardiol Sci Pract. 2014 Oct 16;2014(3):257-90. doi: 10.5339/gcsp.2014.42. eCollection 2014.

本文引用的文献

1
Sildenafil ameliorates effects of inhaled nitric oxide withdrawal.西地那非可改善吸入一氧化氮撤离的影响。
Anesthesiology. 1999 Jul;91(1):307-10. doi: 10.1097/00000542-199907000-00041.
2
Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.西地那非及相关化合物对环鸟苷酸结合的环鸟苷酸特异性磷酸二酯酶(5型)的抑制作用。
Mol Pharmacol. 1999 Jul;56(1):124-30. doi: 10.1124/mol.56.1.124.
3
Vasodilator therapy for primary pulmonary hypertension in children.儿童原发性肺动脉高压的血管扩张剂治疗
Circulation. 1999 Mar 9;99(9):1197-208. doi: 10.1161/01.cir.99.9.1197.
4
Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development.环磷酸鸟苷结合、环磷酸鸟苷特异性磷酸二酯酶(PDE5)基因表达在大鼠肺发育过程中受到调控。
Pediatr Res. 1998 Feb;43(2):163-8. doi: 10.1203/00006450-199802000-00002.
5
Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.原发性肺动脉高压患者长期使用依前列醇(前列环素)治疗可降低肺血管阻力。
N Engl J Med. 1998 Jan 29;338(5):273-7. doi: 10.1056/NEJM199801293380501.
6
The Registry of the International Society of Heart and Lung Transplantation: first official pediatric report--1997.国际心肺移植学会登记处:1997年首份官方儿科报告
J Heart Lung Transplant. 1997 Dec;16(12):1189-206.
7
Pediatric heart-lung transplantation: intermediate-term results.小儿心肺移植:中期结果
J Heart Lung Transplant. 1996 Jul;15(7):692-9.
8
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.持续静脉输注依前列醇(前列环素)与常规疗法治疗原发性肺动脉高压的比较。
N Engl J Med. 1996 Feb 1;334(5):296-301. doi: 10.1056/NEJM199602013340504.

西地那非作为儿童原发性肺动脉高压的一种选择性肺血管扩张剂。

Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension.

作者信息

Abrams D, Schulze-Neick I, Magee A G

机构信息

Department of Paediatric Cardiology, Royal Brompton & Harefield NHS Trust, Sydney Street, London SW3 6NP, UK.

出版信息

Heart. 2000 Aug;84(2):E4. doi: 10.1136/heart.84.2.e4.

DOI:10.1136/heart.84.2.e4
PMID:10908271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1760898/
Abstract

Primary pulmonary hypertension is a rare disease of childhood, which carries a poor prognosis. Patients often present with severe exercise limitation, and untreated life expectancy is less than 1 year. Pharmacological intervention is directed towards reduction of the raised pulmonary artery pressure with vasodilator treatment, initially with calcium antagonists, although more recently long term prostacyclin treatment has shown benefit in some patients. Heart-lung transplantation remains an option for children with severe disease refractory to therapeutic treatment. A 4 year old Bangladeshi girl with dyspnoea, cyanosis, and signs of a low cardiac output, is described. Initial treatment with prostacyclin was gradually reduced, and maintenance treatment with oral sildenafil (Viagra; Pfizer) instituted. At follow up 3 months later, her exercise capacity was greatly improved and she continues to enjoy a good quality of life without obvious side effects. In view of the encouraging initial results, this may become an acceptable adjunct in treating this patient group.

摘要

原发性肺动脉高压是一种罕见的儿童疾病,预后较差。患者常表现出严重的运动受限,未经治疗的预期寿命不到1年。药物干预旨在通过血管扩张剂治疗降低升高的肺动脉压力,最初使用钙拮抗剂,尽管最近长期前列环素治疗已在一些患者中显示出益处。心肺移植仍然是对治疗难治的重症患儿的一种选择。本文描述了一名4岁的孟加拉国女孩,她有呼吸困难、发绀和低心输出量的体征。最初使用前列环素的治疗逐渐减少,并开始使用口服西地那非(伟哥;辉瑞公司)进行维持治疗。3个月后的随访中,她的运动能力有了很大改善,并且继续享受着良好的生活质量,没有明显的副作用。鉴于令人鼓舞的初步结果,这可能成为治疗该患者群体的一种可接受的辅助手段。